The prevalence of this genetic disorder is 1 in 6000 new-borns, where the genetic aberrant induces hyperactivity of the mammalian target of Rapamycin (mTOR) [71] and subsequently causes a spur of multiple hamartomas in organs such as the brain, kidneys, skin, lungs, eyes and heart [71]. The gene discussed is MTOR; the disease is hereditary disease.